Disease progression in melanoma patients with negative sentinel lymph node: does false‐negative specimens entirely account for this phenomenon?

Background  Sentinel lymph node (SLN) status is the most important prognostic factor for subjects with primary melanoma thicker than 1 mm.

[1]  P. Quaglino,et al.  Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  I. Small,et al.  Influence of Sentinel Lymph Node Tumor Burden on Survival in Melanoma , 2010, Annals of Surgical Oncology.

[3]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Paola Savoia,et al.  Skin metastases of malignant melanoma: a clinical and prognostic survey , 2009, Melanoma research.

[5]  O. Nieweg.  False-Negative Sentinel Node Biopsy , 2009, Annals of surgical oncology.

[6]  K. Shannon,et al.  False-negative sentinel node biopsy because of obstruction of lymphatics by metastatic melanoma: the value of ultrasound in conjunction with preoperative lymphoscintigraphy , 2009, Melanoma research.

[7]  Grant W. Carlson,et al.  Regional Recurrence After Negative Sentinel Lymph Node Biopsy for Melanoma , 2008, Annals of surgery.

[8]  S. Di Palma,et al.  Pathology of sentinel lymph nodes for melanoma , 2008, Journal of Clinical Pathology.

[9]  A. Hauschild,et al.  Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. , 2008, Melanoma research.

[10]  C. Ingvar,et al.  Sentinel node biopsy in malignant melanoma: Swedish experiences 1997–2005 , 2008, Acta oncologica.

[11]  O. Nieweg,et al.  New boundaries for lymphatic mapping-report of the Fifth International Sentinel Node Conference. , 2007, Melanoma research.

[12]  R. Turner,et al.  Melanoma recurrence patterns after negative sentinel lymphadenectomy. , 2005, Archives of surgery.

[13]  V. Sondak,et al.  Standard immunostains for melanoma in sentinel lymph node specimens: which ones are most useful? , 2004, Journal of the American Academy of Dermatology.

[14]  R. Scolyer,et al.  Failure to remove true sentinel nodes can cause failure of the sentinel node biopsy technique: Evidence from antimony concentrations in false-negative sentinel nodes from melanoma patients , 2004, Annals of Surgical Oncology.

[15]  H. Hoekstra,et al.  Is sentinel node biopsy beneficial in melanoma patients? A report on 200 patients with cutaneous melanoma. , 2002, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[16]  T. Smith,et al.  Gamma probe‐directed lymphatic mapping and sentinel lymphadenectomy in primary melanoma: Reliability of the procedure and analysis of failures after long‐term follow‐up , 2001, Journal of surgical oncology.

[17]  A. Testori,et al.  Sentinel Lymph Node Biopsy in Cutaneous Melanoma: The WHO Melanoma Program Experience , 2000, Annals of Surgical Oncology.

[18]  M. Mihm,et al.  Outcome of patients with melanoma and histologically negative sentinel lymph nodes. , 1999, Archives of surgery.

[19]  M. Ross,et al.  Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. , 1998, Surgery.

[20]  M. Ross,et al.  Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D L Morton,et al.  Technical details of intraoperative lymphatic mapping for early stage melanoma. , 1992, Archives of surgery.

[22]  C. Stuardi,et al.  [Cutaneous melanoma at the Turin Melanoma Center. I. Survival and correlation with clinical and histologic prognostic factors in 502 patients in stage I (1975-1985)]. , 1986, Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia.

[23]  M. S. Blois,et al.  The Frequency of Local Recurrence and Microsatellites as a Guide to Reexcision Margins for Cutaneous Malignant Melanoma , 1984, Annals of surgery.

[24]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[25]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[26]  P. Carli,et al.  Italian guidelines for staging and follow-up of stage I-II cutaneous melanoma patients , 2007 .

[27]  D. Morton,et al.  The role of sentinel lymph node biopsy in the management of melanoma. , 2007, Advances in surgery.

[28]  PhD Zbigniew I. Nowecki MD,et al.  Survival Analysis and Clinicopathological Factors Associated With False-Negative Sentinel Lymph Node Biopsy Findings in Patients with Cutaneous Melanoma , 2006, Annals of Surgical Oncology.

[29]  P. Quaglino,et al.  Time course and pattern of first relapse in stage I-II primary cutaneous melanoma: a multivariate analysis of disease-free survival in 3,174 patients followed-up at the Turin Melanoma Centre from 1975 to 2004. , 2005 .

[30]  O. Nieweg,et al.  Review and Evaluation of Sentinel Node Procedures in 250 Melanoma Patients With a Median Follow-Up of 6 Years , 2003, Annals of Surgical Oncology.